Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).
China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group Company Limited, has completed the public issuance of the second tranche of its 2026 corporate bonds in mainland China. The bonds, issued in a principal amount of RMB1.4 billion, carry a three-year term with a coupon rate of 1.65% per annum, reflecting the group’s continued access to relatively low-cost funding in the onshore bond market.
The company plans to allocate the net proceeds toward production-related expenditures, including replenishing working capital, repaying interest-bearing debt, and funding project investments in compliance with relevant regulations. This financing move is expected to support the subsidiary’s operational liquidity and expansion needs, potentially strengthening the group’s capital structure and underpinning its growth strategy in China’s pharmaceutical distribution and manufacturing sectors.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company with operations in mainland China, focusing on pharmaceutical manufacturing and commercial distribution. Its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group Company Limited, plays a key role in the group’s financing and business activities in the PRC market.
Average Trading Volume: 19,602,059
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$36.31B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.